Fremanezumab - Teva Pharmaceutical

Drug Profile

Fremanezumab - Teva Pharmaceutical

Alternative Names: Anti-calcitonin gene-related peptide monoclonal antibody; Anti-CGRP monoclonal antibody; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rinat Neuroscience
  • Developer Rinat Neuroscience; Teva Pharmaceutical Industries
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Migraine
  • Phase III Cluster headache

Most Recent Events

  • 27 Nov 2017 Teva plans a phase II trial for Headache (Post-traumatic, prevention) in USA (SC) (NCT03347188)
  • 17 Oct 2017 Preregistration for Migraine (Prevention) in USA (SC)
  • 13 Oct 2017 Teva Branded Pharmaceutical Products, R&D plans the phase III FOCUS trial for Migraine (Prevention) in USA, Belgium, Czechia, Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Spain, Sweden, Switzerland and United Kingdom (SC) (NCT03308968)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top